<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3922121/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC3922121_files/jig.min.css"><script type="text/javascript" src="./PMC3922121_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Circulation. Cardiovascular genetics"><meta name="citation_title" content="Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care"><meta name="citation_authors" content="Marianne K. DeGorter, Rommel G. Tirona, Ute I. Schwarz, Yun-Hee Choi, George K. Dresser, Neville Suskin, Kathryn Myers, GuangYong Zou, Otito Iwuchukwu, Wei-Qi Wei, Russell A. Wilke, Robert A. Hegele, Richard B. Kim"><meta name="citation_date" content="August 2013"><meta name="citation_issue" content="4"><meta name="citation_volume" content="6"><meta name="citation_firstpage" content="400"><meta name="citation_doi" content="10.1161/CIRCGENETICS.113.000099"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3922121/?report=abstract"><meta name="citation_pmid" content="23876492"><meta name="DC.Title" content="Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="Marianne K. DeGorter"><meta name="DC.Contributor" content="Rommel G. Tirona"><meta name="DC.Contributor" content="Ute I. Schwarz"><meta name="DC.Contributor" content="Yun-Hee Choi"><meta name="DC.Contributor" content="George K. Dresser"><meta name="DC.Contributor" content="Neville Suskin"><meta name="DC.Contributor" content="Kathryn Myers"><meta name="DC.Contributor" content="GuangYong Zou"><meta name="DC.Contributor" content="Otito Iwuchukwu"><meta name="DC.Contributor" content="Wei-Qi Wei"><meta name="DC.Contributor" content="Russell A. Wilke"><meta name="DC.Contributor" content="Robert A. Hegele"><meta name="DC.Contributor" content="Richard B. Kim"><meta name="DC.Date" content="2013 Aug"><meta name="DC.Identifier" content="10.1161/CIRCGENETICS.113.000099"><meta name="DC.Language" content="en"><meta property="og:title" content="Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care"><meta property="og:type" content="article"><meta property="og:description" content="A barrier to statin therapy is myopathy associated with elevated systemic drug exposure. Our objective was to examine the association between clinical and pharmacogenetic variables and statin concentrations in patients.In total, 299 patients taking atorvastatin ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC3922121_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC3922121_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC3922121_files/common.min.js">//</script><script type="text/javascript" src="./PMC3922121_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC3922121_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC3922121_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC3922121_files/MathJax.js"></script><script type="text/javascript" src="./PMC3922121_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/pdf/nihms-518688.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="F4FC2C3876C293310000000000A3312A"><link type="text/css" rel="stylesheet" href="./PMC3922121_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC3922121_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC3922121%2F&ncbi_pdid=article&ncbi_phid=F4FC2C3876C293310000000000A3312A'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC3922121_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a><ul id="resources-submenu" class="ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/all/" tabindex="-1" role="menuitem">All Resources</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#chemicals-bioassays" tabindex="-1" role="menuitem" class="expandRight">Chemicals &amp; Bioassays</a><ul class="actual-resources-submenu chemicals-bioassays ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pcassay" title=" Contributed bioactivity data for PubChem Substances " tabindex="-1" role="menuitem">PubChem BioAssay</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pccompound" title=" Unique, standardized chemical structures " tabindex="-1" role="menuitem">PubChem Compound</a></li><li role="presentation"><a href="https://pubchem.ncbi.nlm.nih.gov/search/search.cgi" title=" Searches PubChem Compound by chemical structure " tabindex="-1" role="menuitem">PubChem Structure Search</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pcsubstance" title=" Provides information on the biological activities of small molecules. " tabindex="-1" role="menuitem">PubChem Substance</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/chemicals-bioassays/" tabindex="-1" role="menuitem">All Chemicals &amp; Bioassays Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#dna-rna" tabindex="-1" role="menuitem" class="expandRight">DNA &amp; RNA</a><ul class="actual-resources-submenu dna-rna ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/" title=" DNA and RNA sequences submitted to NCBI " tabindex="-1" role="menuitem">GenBank</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank" title=" Web tool for simple submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: BankIt</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/Sequin/" title=" Software tool for complex submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: Sequin</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nuccore" title=" Nucleotide sequence data in GenBank and RefSeq " tabindex="-1" role="menuitem">Nucleotide Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/popset" title=" Sets of nucleotide sequences representing a population " tabindex="-1" role="menuitem">PopSet</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/" title=" Curated nucleotide and protein sequences produced by NCBI " tabindex="-1" role="menuitem">Reference Sequence (RefSeq)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?" title=" Database of sequences reads from next generation sequencing technologies " tabindex="-1" role="menuitem">Sequence Read Archive (SRA)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/trace.cgi" title=" DNA chromatograms, base calls, and quality estimates for single-pass reads. " tabindex="-1" role="menuitem">Trace Archive</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/unigene" title=" Gene-centered clusters of transcripts and ESTs " tabindex="-1" role="menuitem">UniGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/dna-rna/" tabindex="-1" role="menuitem">All DNA &amp; RNA Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#data-software" tabindex="-1" role="menuitem" class="expandRight">Data &amp; Software</a><ul class="actual-resources-submenu data-software ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml" title=" Program for viewing 3D structures and alignments " tabindex="-1" role="menuitem">Cn3D</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank" title=" Web tool for simple submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: BankIt</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/Sequin/" title=" Software tool for complex submissions of nucleotide sequences " tabindex="-1" role="menuitem">GenBank: Sequin</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="https://pubchem.ncbi.nlm.nih.gov/search/search.cgi" title=" Searches PubChem Compound by chemical structure " tabindex="-1" role="menuitem">PubChem Structure Search</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/SNP/" title=" The SNP database tools page provides links to the general submission guidelines and to the submission handle request. " tabindex="-1" role="menuitem">SNP Submission Tool</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/VAST/vast.html" title=" Tool that generates 3D structural alignments " tabindex="-1" role="menuitem">Vector Alignment Search Tool (VAST)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/data-software/" tabindex="-1" role="menuitem">All Data &amp; Software Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#domains-structures" tabindex="-1" role="menuitem" class="expandRight">Domains &amp; Structures</a><ul class="actual-resources-submenu domains-structures ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml" title=" Program for viewing 3D structures and alignments " tabindex="-1" role="menuitem">Cn3D</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/structure/" title=" Database of 3D macromolecular structures derived from PDB " tabindex="-1" role="menuitem">Structure (Molecular Modeling Database)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/VAST/vast.html" title=" Tool that generates 3D structural alignments " tabindex="-1" role="menuitem">Vector Alignment Search Tool (VAST)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/domains-structures/" tabindex="-1" role="menuitem">All Domains &amp; Structures Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#genes-expression" tabindex="-1" role="menuitem" class="expandRight">Genes &amp; Expression</a><ul class="actual-resources-submenu genes-expression ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gene" title=" Database of gene loci and associated transcripts and proteins " tabindex="-1" role="menuitem">Gene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/geo/" title=" Gene Expression Omnibus (GEO) Database " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Database </a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gds" title=" Curated collections of gene expression data sets " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Datasets</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/geoprofiles/" title=" Database of gene expression Profiles for individual sequences " tabindex="-1" role="menuitem">Gene Expression Omnibus (GEO) Profiles</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/homologene" title=" Sets of homologous eukaryotic genes " tabindex="-1" role="menuitem">HomoloGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/omim" title=" Database of human genes and genetic disorders " tabindex="-1" role="menuitem">Online Mendelian Inheritance in Man (OMIM)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/unigene" title=" Gene-centered clusters of transcripts and ESTs " tabindex="-1" role="menuitem">UniGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genes-expression/" tabindex="-1" role="menuitem">All Genes &amp; Expression Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#genetics-medicine" tabindex="-1" role="menuitem" class="expandRight">Genetics &amp; Medicine</a><ul class="actual-resources-submenu genetics-medicine ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books" title=" Online biomedical books " tabindex="-1" role="menuitem">Bookshelf</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gtr/" title=" Detailed information about genetic tests and labs " tabindex="-1" role="menuitem">Genetic Testing Registry</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/omim" title=" Database of human genes and genetic disorders " tabindex="-1" role="menuitem">Online Mendelian Inheritance in Man (OMIM)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed" title=" Biomedical literature abstracts " tabindex="-1" role="menuitem">PubMed</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/" title=" Free, full-text articles " tabindex="-1" role="menuitem">PubMed Central (PMC)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed/clinical" title=" Directory of PubMed queries about clinical topics " tabindex="-1" role="menuitem">PubMed Clinical Queries</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/rsg/" title=" RefSeqGene reference standards for genomic sequences of well-characterized genes " tabindex="-1" role="menuitem">RefSeqGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genetics-medicine/" tabindex="-1" role="menuitem">All Genetics &amp; Medicine Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#genomes-maps" tabindex="-1" role="menuitem" class="expandRight">Genomes &amp; Maps</a><ul class="actual-resources-submenu genomes-maps ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/dbvar" title=" A database of genomic structural variation " tabindex="-1" role="menuitem">Database of Genomic Structural Variation (dbVar)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genbank/tbl2asn2/" title=" Command-line program for submitting sequence data " tabindex="-1" role="menuitem">GenBank: tbl2asn</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sites/genome" title=" Curated genomic DNA sequences " tabindex="-1" role="menuitem">Genome</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/bioproject/" title=" Central status pages for genome sequencing projects " tabindex="-1" role="menuitem">Genome Project</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mapview/" title=" Tool for searching, viewing and downloading genomic maps and related data " tabindex="-1" role="menuitem">Map Viewer</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nuccore" title=" Nucleotide sequence data in GenBank and RefSeq " tabindex="-1" role="menuitem">Nucleotide Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/popset" title=" Sets of nucleotide sequences representing a population " tabindex="-1" role="menuitem">PopSet</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?" title=" Database of sequences reads from next generation sequencing technologies " tabindex="-1" role="menuitem">Sequence Read Archive (SRA)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Traces/trace.cgi" title=" DNA chromatograms, base calls, and quality estimates for single-pass reads. " tabindex="-1" role="menuitem">Trace Archive</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genomes-maps/" tabindex="-1" role="menuitem">All Genomes &amp; Maps Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#homology" tabindex="-1" role="menuitem" class="expandRight">Homology</a><ul class="actual-resources-submenu homology ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/homologene" title=" Sets of homologous eukaryotic genes " tabindex="-1" role="menuitem">HomoloGene</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/proteinclusters" title=" Clusters of related proteins from prokaryotes and organelles " tabindex="-1" role="menuitem">Protein Clusters</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/homology/" tabindex="-1" role="menuitem">All Homology Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#literature" tabindex="-1" role="menuitem" class="expandRight">Literature</a><ul class="actual-resources-submenu literature ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books" title=" Online biomedical books " tabindex="-1" role="menuitem">Bookshelf</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/nlmcatalog/journals" title=" Information on journals cited by NCBI records " tabindex="-1" role="menuitem">Journals in NCBI Databases</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/mesh" title=" Controlled vocabulary for MEDLINE " tabindex="-1" role="menuitem">MeSH Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK143764/" title=" Introductory articles about NCBI resources " tabindex="-1" role="menuitem">NCBI Handbook</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK3831/" title=" Online, searchable help documentation " tabindex="-1" role="menuitem">NCBI Help Manual</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK1969/" title=" NCBI&#39;s monthly newsletter " tabindex="-1" role="menuitem">NCBI News</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed" title=" Biomedical literature abstracts " tabindex="-1" role="menuitem">PubMed</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/" title=" Free, full-text articles " tabindex="-1" role="menuitem">PubMed Central (PMC)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmed/clinical" title=" Directory of PubMed queries about clinical topics " tabindex="-1" role="menuitem">PubMed Clinical Queries</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pubmedhealth/" title=" Reviews of clinical effectiveness research " tabindex="-1" role="menuitem">PubMed Health</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/literature/" tabindex="-1" role="menuitem">All Literature Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#proteins" tabindex="-1" role="menuitem" class="expandRight">Proteins</a><ul class="actual-resources-submenu proteins ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/biosystems/" title=" Database that groups biomedical literature, small molecules, and sequence data in terms of biological relationships. " tabindex="-1" role="menuitem">BioSystems</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/cdd" title=" Database of conserved protein domains represented by multiple sequence alignments " tabindex="-1" role="menuitem">Conserved Domain Database (CDD)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK25501/" title=" URL application programming interface for searching, linking and downloading data within NCBI&#39;s Entrez system " tabindex="-1" role="menuitem">E-Utilities</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/proteinclusters" title=" Clusters of related proteins from prokaryotes and organelles " tabindex="-1" role="menuitem">Protein Clusters</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/protein" title=" Protein sequence data " tabindex="-1" role="menuitem">Protein Database</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/refseq/" title=" Curated nucleotide and protein sequences produced by NCBI " tabindex="-1" role="menuitem">Reference Sequence (RefSeq)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/proteins/" tabindex="-1" role="menuitem">All Proteins Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#sequence-analysis" tabindex="-1" role="menuitem" class="expandRight">Sequence Analysis</a><ul class="actual-resources-submenu sequence-analysis ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" title=" Tool for finding local regions of sequence similarity " tabindex="-1" role="menuitem">BLAST (Basic Local Alignment Search Tool)</a></li><li role="presentation"><a href="https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&amp;PAGE_TYPE=BlastDocs&amp;DOC_TYPE=Download" title=" BLAST programs for a local computer " tabindex="-1" role="menuitem">BLAST (Stand-alone)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/blink.cgi?mode=query" title=" Pre-computed reports showing proteins with similar sequences " tabindex="-1" role="menuitem">BLAST Link (BLink)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi" title=" Locates conserved domains within a protein sequence " tabindex="-1" role="menuitem">Conserved Domain Search Service (CD Search)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/protmap.cgi" title=" Maps proteins from a COG/VOG back to its genome " tabindex="-1" role="menuitem">Genome ProtMap</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/gbench/" title=" Stand-alone application for analyzing sequence data " tabindex="-1" role="menuitem">Genome Workbench</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/genomes/FLU/" title=" Data from the NIAID Influenza Genome Sequencing Project " tabindex="-1" role="menuitem">Influenza Virus</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/tools/primer-blast/" title=" Designs PCR primers and analyzes them for target specificity using BLAST. " tabindex="-1" role="menuitem">Primer-BLAST</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/static/prosplign/prosplign.html" title=" Tool for aligning proteins to genomic DNA " tabindex="-1" role="menuitem">ProSplign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/sutils/splign/" title=" Tool for aligning transcripts to genomic DNA " tabindex="-1" role="menuitem">Splign</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/sequence-analysis/" tabindex="-1" role="menuitem">All Sequence Analysis Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#taxonomy" tabindex="-1" role="menuitem" class="expandRight">Taxonomy</a><ul class="actual-resources-submenu taxonomy ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/taxonomy" title=" The NCBI taxonomy tree in Entrez " tabindex="-1" role="menuitem">Taxonomy</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Root" title=" Displays and links Entrez data to each taxonomic node " tabindex="-1" role="menuitem">Taxonomy Browser</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/Taxonomy/CommonTree/wwwcmt.cgi" title=" Creates custom taxonomic trees " tabindex="-1" role="menuitem">Taxonomy Common Tree</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/taxonomy/" tabindex="-1" role="menuitem">All Taxonomy Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#training-tutorials" tabindex="-1" role="menuitem" class="expandRight">Training &amp; Tutorials</a><ul class="actual-resources-submenu training-tutorials ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/education/" title=" Central page providing links to tutorials and training materials " tabindex="-1" role="menuitem">NCBI Education Page</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK143764/" title=" Introductory articles about NCBI resources " tabindex="-1" role="menuitem">NCBI Handbook</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK3831/" title=" Online, searchable help documentation " tabindex="-1" role="menuitem">NCBI Help Manual</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/books/NBK1969/" title=" NCBI&#39;s monthly newsletter " tabindex="-1" role="menuitem">NCBI News</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/training-tutorials/" tabindex="-1" role="menuitem">All Training &amp; Tutorials Resources...</a></li></ul></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#variation" tabindex="-1" role="menuitem" class="expandRight">Variation</a><ul class="actual-resources-submenu variation ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/dbvar" title=" A database of genomic structural variation " tabindex="-1" role="menuitem">Database of Genomic Structural Variation (dbVar)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/gap" title=" Genotype/Phenotype association studies " tabindex="-1" role="menuitem">Database of Genotypes and Phenotypes (dbGaP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/snp" title=" Database of nucleotide sequence polymorphisms " tabindex="-1" role="menuitem">Database of Single Nucleotide Polymorphisms (dbSNP)</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/projects/SNP/" title=" The SNP database tools page provides links to the general submission guidelines and to the submission handle request. " tabindex="-1" role="menuitem">SNP Submission Tool</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/variation/" tabindex="-1" role="menuitem">All Variation Resources...</a></li></ul></li></ul></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a><ul id="howto-submenu" class="ui-ncbibasicmenu" role="menu"><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/all/#howtos" tabindex="-1" role="menuitem">All How To</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/chemicals-bioassays/#howtos" tabindex="-1" role="menuitem">Chemicals &amp; Bioassays</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/dna-rna/#howtos" tabindex="-1" role="menuitem">DNA &amp; RNA</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/data-software/#howtos" tabindex="-1" role="menuitem">Data &amp; Software</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/domains-structures/#howtos" tabindex="-1" role="menuitem">Domains &amp; Structures</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genes-expression/#howtos" tabindex="-1" role="menuitem">Genes &amp; Expression</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genetics-medicine/#howtos" tabindex="-1" role="menuitem">Genetics &amp; Medicine</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/genomes-maps/#howtos" tabindex="-1" role="menuitem">Genomes &amp; Maps</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/homology/#howtos" tabindex="-1" role="menuitem">Homology</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/literature/#howtos" tabindex="-1" role="menuitem">Literature</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/proteins/#howtos" tabindex="-1" role="menuitem">Proteins</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/sequence-analysis/#howtos" tabindex="-1" role="menuitem">Sequence Analysis</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/taxonomy/#howtos" tabindex="-1" role="menuitem">Taxonomy</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/training-tutorials/#howtos" tabindex="-1" role="menuitem">Training &amp; Tutorials</a></li><li role="presentation"><a href="http://www.ncbi.nlm.nih.gov/guide/variation/#howtos" tabindex="-1" role="menuitem">Variation</a></li></ul></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3922121%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3922121%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" style="visibility: hidden;"><img src="./PMC3922121_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="http://www.ncbi.nlm.nih.gov/pmc/?term=hhs%20author%20manuscript[filter]&amp;cmd=search&amp;EntrezSystem2.PEntrez.Pmc.Pmc_LimitsTab.LimitsOff=true" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC3922121</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC3922121_files/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="http://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="http://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="http://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="http://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div>Circ Cardiovasc Genet. Author manuscript; available in PMC 2014 Aug 1.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=23876492" target="pmc_ext" ref="reftype=publisher&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CFree%20Access&amp;rendering-type=normal"><span class="cit">Circ Cardiovasc Genet. 2013 Aug; 6(4): 400–408. </span></a></div><span class="fm-vol-iss-date">Published online 2013 Jul 22. </span> <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1161%2FCIRCGENETICS.113.000099" target="pmc_ext" ref="reftype=other&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1161/CIRCGENETICS.113.000099</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3922121</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS518688</span></div></div></div></div></div><h1 class="content-title">Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=DeGorter%20MK%5Bauth%5D">Marianne K. DeGorter</a>, PhD,<sup>1,</sup><sup>2</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Tirona%20RG%5Bauth%5D">Rommel G. Tirona</a>, PhD,<sup>1,</sup><sup>2</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Schwarz%20UI%5Bauth%5D">Ute I. Schwarz</a>, MD, PhD,<sup>1,</sup><sup>2</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Choi%20YH%5Bauth%5D">Yun-Hee Choi</a>, PhD,<sup>3</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Dresser%20GK%5Bauth%5D">George K. Dresser</a>, MD, PhD,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Suskin%20N%5Bauth%5D">Neville Suskin</a>, MBChB, MSc,<sup>1,</sup><sup>3</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Myers%20K%5Bauth%5D">Kathryn Myers</a>, MD,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Zou%20G%5Bauth%5D">GuangYong Zou</a>, PhD,<sup>3</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Iwuchukwu%20O%5Bauth%5D">Otito Iwuchukwu</a>, PhD,<sup>5</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Wei%20WQ%5Bauth%5D">Wei-Qi Wei</a>, MMed, PhD,<sup>5</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Wilke%20RA%5Bauth%5D">Russell A. Wilke</a>, MD, PhD,<sup>5</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Hegele%20RA%5Bauth%5D">Robert A. Hegele</a>, MD,<sup>1,</sup><sup>5</sup> and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20RB%5Bauth%5D">Richard B. Kim</a>, MD<sup>1,</sup><sup>2</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id1081853_ai" style="display:none"><div class="fm-affl" lang="en"><sup>1</sup>Dept of Medicine, The University of Western Ontario, London, Canada</div><div class="fm-affl" lang="en"><sup>2</sup>Dept of Physiology &amp; Pharmacology, The University of Western Ontario, London, Canada</div><div class="fm-affl" lang="en"><sup>3</sup>Dept of Epidemiology &amp; Biostatistics, The University of Western Ontario, London, Canada</div><div class="fm-affl" lang="en"><sup>4</sup>Vanderbilt University Medical Center, Nashville, TN</div><div class="fm-affl" lang="en"><sup>5</sup>Robarts Research Institute, The University of Western Ontario, London, Canada</div><div id="CR1"><strong>Correspondence:</strong> Richard B. Kim, MD ALL-152 LHSC – University Hospital 339 Windermere Road London, Ontario N6A 5A5 Canada Tel: 1 519 663 3553 Fax: 1 519 663 3232 <span class="before-email-separator">; </span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.no.cshl@mik.drahcir" class="oemail">ac.no.cshl@mik.drahcir</a></div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" class="pmctoggle" rid="id1081853_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" class="pmctoggle" rid="id1081853_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id1081853_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright notice</a>  and <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Disclaimer</a></div><div><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#FN2">Publisher's Disclaimer</a></div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>The publisher's final edited version of this article is available free at <a href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=23876492" target="pmc_ext" ref="reftype=publisher&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CFree%20Access&amp;rendering-type=normal">Circ Cardiovasc Genet</a></div><div>See other articles in PMC that <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="__abstractid1030492" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid1030492title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3>Background</h3><p id="P1" class="p p-first-last">A barrier to statin therapy is myopathy associated with elevated systemic drug exposure. Our objective was to examine the association between clinical and pharmacogenetic variables and statin concentrations in patients.</p></div><div id="S2" class="sec"><h3>Methods and Results</h3><p id="P2" class="p p-first-last">In total, 299 patients taking atorvastatin or rosuvastatin were prospectively recruited at an outpatient referral center. The contribution of clinical variables and transporter gene polymorphisms to statin concentration was assessed using multiple linear regression. We observed 45-fold variation in statin concentration among patients taking the same dose. After adjustment for gender, age, body mass index, ethnicity, dose, and time from last dose, <em>SLCO1B1</em> c.521T&gt;C (p &lt; 0.001) and <em>ABCG2</em> c.421C&gt;A (p &lt; 0.01) were important to rosuvastatin concentration (adjusted R<sup>2</sup> = 0.56 for the final model). Atorvastatin concentration was associated with <em>SLCO1B1</em> c.388A&gt;G (p &lt; 0.01) and c.521T&gt;C (p &lt; 0.05), and 4β-hydroxycholesterol, a CYP3A activity marker (adjusted R<sup>2</sup> = 0.47). A second cohort of 579 patients from primary and specialty care databases were retrospectively genotyped. In this cohort, genotypes associated with statin concentration were not differently distributed among dosing groups, implying providers had not yet optimized each patient's risk-benefit ratio. Nearly 50% of patients in routine practice taking the highest doses were predicted to have statin concentrations greater than the 90<sup>th</sup> percentile.</p></div><div id="S3" class="sec sec-last"><h3>Conclusions</h3><p id="P3" class="p p-first-last">Interindividual variability in statin exposure in patients is associated with uptake and efflux transporter polymorphisms. An algorithm incorporating genomic and clinical variables to avoid high atorvastatin and rosuvastatin levels is described; further study will determine if this approach reduces incidence of statin-myopathy.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">statin therapy, pharmacogenetics, pharmacokinetics, drug transporters</span></div></div><div id="S4" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S4title">Introduction</h2><p id="P4" class="p p-first">The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins, are commonly prescribed and proven to be effective in reducing cardiovascular event risk by lowering plasma concentration of low-density lipoprotein cholesterol (LDL-C)<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660416">1</a></sup>. A recent report indicates that 25% of Americans over age 45 takes a statin, and it is predicted the number will grow as the populations of Westernized countries continue to age and maintain unhealthy lifestyles<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660422">2</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R3" rid="R3" class=" bibr popnode">3</a></sup>. A significant barrier to statin therapy is skeletal muscle toxicity associated with elevated systemic drug exposure<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660434">4</a></sup>. Up to 10% of statin-treated individuals will experience muscle pain or weakness, and in rare cases, life-threatening rhabdomyolysis occurs<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660421">5</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660402">7</a></sup>. Currently, we do not fully understand the drug exposure necessary for optimal statin therapy, making it difficult to predict an individual's dose requirement to maximize LDL-C lowering, while minimizing the risk for muscle injury.</p><p id="P5">Remarkably few data are readily available regarding interpatient variability in plasma statin level, especially considering the number of large multicenter clinical trials of cardiovascular outcomes with statins performed to date. Until recently, drug metabolizing enzymes such as cytochrome P450 enzymes (CYPs) were considered to be the major determinants of statin disposition. However, studies from our laboratory and others suggest that statins, particularly the pharmacologically active acid forms of statins, are highly dependent on drug transporter proteins for their disposition and efficacy<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660417">8</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660428">9</a></sup>.</p><p id="P6" class="p p-last">Our objective was to characterize the relationship between drug transporter polymorphisms and interindividual variability in plasma statin concentration, which, in the clinical situation, is not well understood. We measured 4β-hydroxycholesterol concentration as a marker of CYP3A metabolic activity in vivo, and lathosterol concentration to assess the efficacy of statin-mediated inhibition of endogenous cholesterol synthesis, as well as its relationship to statin concentration. Taken together, these data describe the relative contribution of transport genetics and metabolism to interindividual variability in statin pharmacokinetics and response.</p></div><div id="S5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S5title">Methods</h2><div id="S6" class="sec sec-first"><h3>Study population</h3><p id="P7" class="p p-first-last">We prospectively invited adult outpatients at London Health Sciences Center (LHSC, London, Canada) taking atorvastatin or rosuvastatin daily to participate. Patients were excluded if they were taking atorvastatin or rosuvastatin in an alternate day dosing regimen, or if they had not taken their last atorvastatin or rosuvastatin dose within 24 hours of their clinic visit and blood draw. All patients had been taking atorvastatin or rosuvastatin at the same dose for at least six weeks prior to participation, with the exception of one patient who had been switched from 40 mg to 80 mg one week prior to blood sampling to achieve better cholesterol lowering. The study was conducted between August 2009 and May 2011. A detailed medical history was obtained, and the time of the last oral statin dose in relation to plasma level measurement was recorded. Ethnicity was self-reported. LDL-C response was defined by attainment of LDL-C target values according to the 2009 Canadian Lipid Guidelines<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660433">1</a></sup> and by the clinical judgment of the treating physician. All subjects provided written informed consent. The study protocol was approved by the Research Ethics Board of the University of Western Ontario (London, Canada).</p></div><div id="S7" class="sec"><h3>Sample collection</h3><p id="P8" class="p p-first-last">A single venous 8 mL blood sample was drawn into EDTA-containing tubes, and placed immediately on ice. Samples were centrifuged 2,000 × g for 10 minutes; plasma was collected and stored at −80 °C until further analysis. Genomic DNA was isolated from blood samples using the Gentra Puregene extraction kit (Qiagen, Alameda, CA, USA).</p></div><div id="S8" class="sec"><h3>Retrospective statin dosing analysis</h3><p id="P9" class="p p-first-last">We retrospectively examined genotype, clinical variables, and statin dose in a separate cohort comprised of outpatients from LHSC and Vanderbilt University Medical Center (BioVU, Nashville, Tennessee).</p></div><div id="S9" class="sec"><h3>BioVU</h3><p id="P10" class="p p-first-last">BioVU at Vanderbilt University is a large collection of DNA samples linked to a comprehensive EMR<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660415">10</a></sup>. BioVU is a dynamic clinical practice-based cohort, nested within an even larger database containing a secure, de-identified copy of the entire EMR utilized by Vanderbilt University Medical Center. Referred to as the Synthetic Derivative (SD), this practice-derived database incorporates clinical information from multiple sources, including diagnostic and procedural codes, as well as provider progress notes, hospital admissions, discharge summaries, clinical laboratory data, and medication data.</p></div><div id="S10" class="sec"><h3>Determination of plasma statin concentration</h3><p id="P11" class="p p-first-last">All chemical and deuterated standards were obtained from Toronto Research Chemicals (North York, Canada). Plasma aliquots of 100 μL were precipitated in 300 μL acetonitrile containing internal standard d5-atorvastatin or d6-rosuvastatin, and centrifuged at 14,000 rpm for 20 minutes at 4 °C. The supernatant was diluted 1:1 in 0.05% formic acid. Analytes were separated using mobile phases 0.05% formic acid in water and 0.05% formic acid in acetonitrile, starting at a ratio of 70:30, with a gradient to ratio of 10:90. Concentrations of rosuvastatin and atorvastatin were measured by liquid chromatography-mass spectrometry (LCMS) instrumentation and transitions as previously described <sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660432">11</a></sup>.</p></div><div id="S11" class="sec"><h3>Determination of lathosterol and 4β-hydroxycholesterol concentrations</h3><p id="P12" class="p p-first-last">Sterol concentrations were measured according to published methods for LCMS <sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660437">12</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660426">13</a></sup>. Lathosterol, 4β-hydroxycholesterol, and 4β-hydroxycholesterol-d7 were obtained from Avanti Polar Lipids (Alabaster, Alabama), and lathosterol-d4 was obtained from CDN Isotopes (Pointe-Claire, Canada). All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Standard curves ranging from 0-50 μg/mL lathosterol were prepared in 1% fatty acid-free bovine serum albumin in phosphate-buffered saline. Aliquots of 50 μL of plasma or standard curve were saponified in 1 mL of 1M KOH in ethanol for 1 hour at 37 °C. The samples were extracted twice, in 750 μL of hexanes each time. After evaporation at 80 °C to dryness, a mixture of the following derivatization reagents was added to each sample: 15 mg 2-methyl-6-nitrobenzoic anhydride, 4.5 mg 4-dimethylaminopyridine, 12 mg picolinic acid, 225 μL pyridine, and 30 μL triethylamine. Samples were incubated with the derivatization reagents at 80 °C for 1 hour, extracted in 1 mL of hexanes, and evaporated at 80 °C to dryness. Samples were reconstituted in 20 μL 0.9% NaCl and 80 μL water; 20 μL of sample was injected on an Eclipse Plus C18 column (1.8 μm pore size; 2.1 × 100 mm; Agilent Technologies, Mississauga, Canada) attached to an Agilent 1290 Infinity ultra high pressure liquid chromatography system (Agilent Technologies) coupled with a TSQ Quantum triple-quadrupole mass spectrometer (Thermo Scientific). Analytes were separated and eluted with a gradient from 80% to 98% methanol:acetonitrile (1:1). The transition used for lathosterol was m/z 555.3 to 513.8. The transition used for 4β-hydroxycholesterol was m/z 635.4 to 146.5. Interday variability was less than 25% for lathosterol and less than 30% for 4β-hydroxycholesterol, at relevant concentrations.</p></div><div id="S12" class="sec"><h3>Determination of total cholesterol</h3><p id="P13" class="p p-first-last">Total cholesterol was measured by the enzymatic colorimetric method, using the Cholesterol E kit from Wako (Richmond, VA). Samples were measured in triplicate using the microplate procedure, according to manufacturer's directions.</p></div><div id="S13" class="sec"><h3>Genotyping</h3><p id="P14" class="p p-first">We identified single nucleotide polymorphisms (SNPs) with a minor allelic frequency greater than 10% in genes encoding drug transporters for which statins are known substrates, and genotyped SNPs that have been demonstrated to have a functional effect on one or more substrates in vivo. Genotype was determined by TaqMan assay (Applied Biosystems, Foster City, CA) for uptake transporter polymorphisms <em>SLCO1B1</em> c.388A&gt;G (rs2306283); <em>SLCO1B1</em> c.521T&gt;C (rs4149056); <em>SLCO1B3</em> c.699G&gt;A (rs7311358); <em>SLCO2B1</em> c.935G&gt;A (rs12422149), and efflux transporter polymorphisms <em>ABCB1</em> c.3435C&gt;T (rs1045642); <em>ABCC2</em> c.1249G&gt;A (rs2273697); and <em>ABCG2</em> c.421C&gt;A (rs2231142). For the atorvastatin group, polymorphisms in the drug metabolizing enzymes <em>CYP3A4</em> (rs35599367) and <em>CYP3A5</em> (rs776746) were also assessed. Patients in the rosuvastatin group were also genotyped for CYP2C9 *2 (rs1799853) and CYP2C9 *3 (rs1057910). The SNPs assessed in the present study are summarized in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#SD1" rid="SD1" class=" supplementary-material">Supplementary Table 1</a>. Missing genotypes ranged from 0% to 0.7%, depending on the polymorphism. We repeated genotyping of 10% of the samples; 100% of replicated genotypes were concordant. Haplotypes were determined using the haplo.stats library in R using an indirect design matrix and linear regression was conducted by comparing alternative haplotypes to the reference haplotype <em>SLCO1B1</em> c.388A-c521T.</p><p id="P15" class="p p-last">Hardy-Weinberg equilibrium was tested using the Chi-square method of the genetics package of R. All genotypes tested were in Hardy-Weinberg equilibrium with the exception of <em>ABCB1</em> c.3435C&gt;T (p = 0.010) and <em>SLCO1B1</em> c.521T&gt;C (p = 0.041). Genotypes associated with statin concentration were not differently distributed between Caucasians and other ethnicities in our patient cohort, by Chi-square test.</p></div><div id="S14" class="sec"><h3>Statistical analysis</h3><p id="P16" class="p p-first">Statistical analysis was performed using the statistical software R<sup>14</sup> and GraphPad Prism 5 (La Jolla, CA). Differences in statin concentration with respect to each dose group were assessed by Tukey's multiple comparisons tests. We defined the explainable variability as the variability attributed to characteristics other than dose and time from last dose. We calculated this by totaling the sum of squares for each final model and assessing the proportion contributed by the genetic variables.</p><p id="P17" class="p p-last">For log-transformed rosuvastatin concentration, the effect sizes detectable with a power of 0.80 or higher are 0.141, 0.145 and 0.187 for <em>SLCO1B1</em> c.521T&gt;C, <em>SLCO1B1</em> c.388A&gt;G, and <em>ABCG2</em> c.421C&gt;A, respectively. For log-transformed atorvastatin concentration, the effect sizes detectable with a power of 0.80 or higher are 0.274, 0.223 and 0.324 for <em>SLCO1B1</em> c.521T&gt;C, <em>SLCO1B1</em> c.388A&gt;G, and <em>ABCG2</em> c.421C&gt;A, respectively.</p></div><div id="S15" class="sec"><h3>Multiple linear regression analysis</h3><p id="P18" class="p p-first-last">Statin concentration was log-transformed to adjust for right-skew. Only those patients with blood sampling times after the t<sub>max</sub> of the statin were included (1.5 hours and 4.0 hours for atorvastatin and rosuvastatin, respectively<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660419">11</a></sup>). Different genetic models–dominant, co-dominant, recessive, and additive models–were considered for each transporter polymorphism and the model that best described the fit with log-transformed statin concentration or lathosterol concentration was chosen. Each polymorphism was assessed for association with log statin concentration with a cut-off p-value of 0.20 for further inclusion in the multiple linear regression model. <em>SLCO1B1</em> c.521T&gt;C and c.388A&gt;G, and <em>ABCG2</em> c.421C&gt;A, were included in the model as additive models. In the additive model, homozygous wildtype genotypes were coded as 0, heterozygous genotypes were coded as 1, and homozygous variant genotypes were coded as 2. Regression analysis was performed by a step-wise search. All models were adjusted for the demographic and dosing variables age, gender, body mass index (BMI), ethnicity, statin dose, and hours from last dose. Of these variables, age, dose, and time from last dose were statistically significant. Next, the number of concomitant medications or presence of the specific medications ezetimibe, niacin, and fibrate were assessed for their contribution to the model and retained if p &lt; 0.20. 4β-hydroxycholesterol values and transporter and drug metabolizing enzyme genotypes were similarly introduced into the model. In the final model, only those variables with p &lt; 0.05 were retained, with the exception of the demographic and dosing variables listed above.</p></div><div id="S16" class="sec sec-last"><h3>Dosing algorithm</h3><p id="P19" class="p p-first-last">Maximum doses predicted to result in statin concentrations less than the 90<sup>th</sup> percentile were calculated based on our linear regression models. The 90<sup>th</sup> percentile was determined by adjusting the atorvastatin or rosuvastatin concentrations measured in our population to the concentration predicted at the average time of the blood sampling across the population (11.5 hours for atorvastatin and 12.9 hours for rosuvastatin). For covariates that were not significant in the model, we substituted the average population value: predicted concentration was calculated for a hypothetical Caucasian patient of our average population height and weight (body mass index of 29.0 kg/m<sup>2</sup> for atorvastatin and 30.1 kg/m<sup>2</sup> rosuvastatin), and for atorvastatin, average 4β-hydroxycholesterol concentration (22 ng/ml). Age was rounded to the nearest 5-year interval.</p></div></div><div id="S17" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S17title">Results</h2><div id="S18" class="sec sec-first"><h3>Patient characteristics</h3><p id="P20" class="p p-first-last">The patients’ baseline characteristics are summarized in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. In total, 299 patients were enrolled in the study, with 134 taking atorvastatin and 165 patients on rosuvastatin therapy. Of these patients, 3 taking rosuvastatin and 6 taking atorvastatin had undetectable statin levels, and were excluded from further analysis. Two patients taking rosuvastatin were excluded from lathosterol-related analysis, due to inability to measure lathosterol or total cholesterol. A list of the concomitant medications observed in our population is provided in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#SD1" rid="SD1" class=" supplementary-material">Supplemental Table 2</a>.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T1/" target="table" rid-ob="ob-T1" rid-figpopup="T1" class="table img_link icnblk_img figpopup"><img alt="Table 1" title="Table 1" class="small-thumb" src="./PMC3922121_files/saved_resource" src-large="/pmc/articles/PMC3922121/table/T1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T1/" target="table" rid-figpopup="T1" rid-ob="ob-T1">Table 1</a></div><!--caption a4--><div><span>Population characteristics of prospective cohort of atorvastatin- and rosuvastatin-treated patients</span></div></div></div></div><div id="S19" class="sec"><h3>Rosuvastatin concentration</h3><p id="P21" class="p p-first">We observed up to 45-fold variability in plasma rosuvastatin concentration among individuals on the same dose (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>). In patients taking 5, 10, 20, or 40 mg rosuvastatin daily, mean plasma concentration of rosuvastatin was 1.6 ng/mL (SD 1.8), 3.5 ng/mL (2.9), 6.3 ng/mL (5.3), and 9.8 ng/mL (8.6), respectively. There was a significant difference in plasma rosuvastatin concentration between those taking 5 mg vs. 10 mg, 20 mg or 40 mg (p &lt; 0.001 for all) and for those taking 10 mg vs. 20 mg or 40 mg (p &lt; 0.01 and p &lt; 0.001, respectively; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><img src="./PMC3922121_files/nihms-518688-f0001.gif" class="small-thumb" alt="Figure 1" title="Figure 1" src-large="/pmc/articles/PMC3922121/bin/nihms-518688-f0001.jpg"></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a4--><div><span>Prospective analysis of atorvastatin (A) plasma concentrations in patients taking 10, 20, 40, or 80 mg daily, and rosuvastatin (B) plasma concentrations in patients taking 5, 10, 20, or 40 mg daily. Rosuvastatin concentrations were collected within 0</span> <strong>...</strong></div></div></div><p id="P22" class="p p-last">In order to assess the association of clinical and pharmacogenetic variables with the rosuvastatin levels observed, we performed multiple linear regression analysis. Only those patients with blood drawn at least four hours after their last oral dose were included in this analysis (n = 130). Multiple linear regression analysis indicated that plasma rosuvastatin concentration was higher in individuals with the reduced function hepatic uptake transporter allele <em>SLCO1B1</em> c.521C (p &lt; 0.0001), and the reduced function efflux transporter polymorphism <em>ABCG2</em> c.421A (p &lt; 0.05). Age also contributed to plasma rosuvastatin level (p &lt; 0.01) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T2/" target="true" class="fig-table-link table figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The adjusted R<sup>2</sup> value of the model was 0.56. Similar results were obtained using <em>SLCO1B1</em> haplotypes (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#SD1" rid="SD1" class=" supplementary-material">Supplemental Table 5</a>). Polymorphisms in transporter genes <em>SLCO1B1</em> and <em>ABCG2</em> contributed to 88% of the explainable variability, after adjusting for dose and time from last dose. The variables gender, ethnicity, BMI, and <em>SLCO1B1</em> c.388, <em>SLCO1B3, SLCO2B1, ABCB1, ABCC2</em>, and <em>CYP2C9</em> genotype were not significantly associated with rosuvastatin concentration.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T2/" target="table" rid-ob="ob-T2" rid-figpopup="T2" class="table img_link icnblk_img figpopup"><img alt="Table 2" title="Table 2" class="small-thumb" src="./PMC3922121_files/saved_resource(1)" src-large="/pmc/articles/PMC3922121/table/T2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T2/" target="table" rid-figpopup="T2" rid-ob="ob-T2">Table 2</a></div><!--caption a4--><div><span>Plasma statin concentration linear regression model coefficients from prospective cohort</span></div></div></div></div><div id="S20" class="sec"><h3>Atorvastatin concentration</h3><p id="P23" class="p p-first">Similar to rosuvastatin, we observed 45-fold or higher variability between patients on the same daily atorvastatin dose (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a>). In patients taking 10, 20, 40, or 80 mg atorvastatin daily, mean plasma concentration of atorvastatin was 0.9 ng/mL (SD 1.0), 2.0 ng/mL (1.7), 3.0 ng/mL (3.5), and 6.0 ng/mL (8.2), respectively. There was a significant difference in plasma atorvastatin concentration between those taking 20 mg, 40 mg, or 80 mg vs. 10 mg (p &lt; 0.05, p &lt; 0.001, and p &lt; 0.001, respectively) and between those taking 20 mg vs 80 mg (p &lt; 0.05; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a>).</p><p id="P24" class="p p-last">Multiple linear regression analysis indicated that plasma atorvastatin concentration was higher in individuals with the <em>SLCO1B1</em> c.521C allele (p &lt; 0.05) but lower in those patients with the <em>SLCO1B1</em> c.388G allele (p &lt; 0.01). 4β-hydroxycholesterol also contributed significantly to the variability observed (p &lt; 0.01). In addition, age was a significant predictor of atorvastatin level (p &lt; 0.01) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T2/" target="true" class="fig-table-link table figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The adjusted R<sup>2</sup> value of the model was 0.47. <em>SLCO1B1</em> haplotype-based analysis produced similar results (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#SD1" rid="SD1" class=" supplementary-material">Supplemental Table 5</a>). In contrast to rosuvastatin, the genetic component of the model contributed only 38% of the explainable variability observed. Metabolism, as measured by 4β-hydroxycholesterol concentration, accounted for an additional 30% of the explainable variability in atorvastatin concentration. A list of CYP3A inhibitors and inducers prescribed to patients taking atorvastatin is provided in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#SD1" rid="SD1" class=" supplementary-material">Supplemental Table 6</a>. Similar results were obtained when 4β-hydroxycholesterol levels were normalized by total cholesterol. The following variables were not significantly associated with atorvastatin concentration: gender, ethnicity, BMI, and <em>SLCO1B3, SLCO2B1, ABCB1, ABCC2, ABCG2, CYP3A4</em> and <em>CYP3A5</em> genotype.</p></div><div id="S21" class="sec"><h3>Lathosterol concentration</h3><p id="P25" class="p p-first-last">The mean lathosterol concentration in patients taking atorvastatin was 3.9 μg/mL (SD 2.1) and rosuvastatin was 3.4 μg/mL (2.2). In patients taking atorvastatin, lathosterol concentration was lower in patients taking a higher dose of atorvastatin (p &lt; 0.01), however, there was no significant association between rosuvastatin or atorvastatin concentrations and lathosterol concentration detected in this population. In both groups, lathosterol was associated with total cholesterol, and was higher in patients taking ezetimibe (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T3/" target="true" class="fig-table-link table figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). The adjusted R<sup>2</sup> value of the model of lathosterol concentration in atorvastatin-treated patients was 0.08; for rosuvastatin-treated patients the adjusted R<sup>2</sup> value was 0.39.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T3"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T3/" target="table" rid-ob="ob-T3" rid-figpopup="T3" class="table img_link icnblk_img figpopup"><img alt="Table 3" title="Table 3" class="small-thumb" src="./PMC3922121_files/saved_resource(2)" src-large="/pmc/articles/PMC3922121/table/T3/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T3/" target="table" rid-figpopup="T3" rid-ob="ob-T3">Table 3</a></div><!--caption a4--><div><span>Lathosterol plasma concentration linear regression model coefficients from prospective cohort</span></div></div></div></div><div id="S22" class="sec"><h3>LDL-C lowering response to rosuvastatin</h3><p id="P26" class="p p-first-last">Despite the lack of association between lathosterol level and statin level, some insight can be gained from this rare opportunity to examine lipid-lowering response in combination with plasma statin concentration. We examined rosuvastatin acid concentrations in patients taking 40 mg rosuvastatin daily, for whom no higher dose or more potent statin is available, and included only those with blood taken 9 to 24 hours post-dose, to be within the linear range of statin elimination and minimize the variability associated with the peak statin absorption. Patients who were not at target LDL-C (n = 12) had a mean plasma rosuvastatin concentration of 9.183 ng/mL (SD 1.6; 13.6 hours post dose) compared with a mean plasma concentration of 7.497 ng/mL (SD 1.8; 13.7 hours post dose) for those who were at target (n = 13); the difference between the two groups was not significant (p = 0.45). There was also a trend toward lower lathosterol level in those individuals at target compared with those not at target (3.4 μg/mL (SD 0.49) vs. 4.7 μg/mL (0.45), p = 0.065). Notably, there is a higher proportion of <em>SLCO1B1</em> c.521T&gt;C variants in the non-responders (8 of 12 patients are <em>SLCO1B1</em> c.521CT heterozygotes) vs. responders (3 of 13 heterozygotes; p = 0.047, Fisher's exact test).</p></div><div id="S23" class="sec"><h3>Statin dosing algorithm</h3><p id="P27" class="p p-first-last">In <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F2/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>, we summarize recommendations for maximum atorvastatin and rosuvastatin doses, based on a patient's age and transporter genotype, and the linear regression analysis described above. These doses are predicted to result in plasma concentrations that remain lower than the 90<sup>th</sup> percentile, a value chosen to reflect the fact that 10% of individuals will experience statin-related muscle complaints.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><img src="./PMC3922121_files/nihms-518688-f0002.gif" class="small-thumb" alt="Figure 2" title="Figure 2" src-large="/pmc/articles/PMC3922121/bin/nihms-518688-f0002.jpg"></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a4--><div><span>Rosuvastatin and atorvastatin dosing decision support algorithm. Doses are the maximum doses that result in a predicted rosuvastatin or atorvastatin concentration that is less than the 90th percentile. In patients taking atorvastatin, dose should be lowered</span> <strong>...</strong></div></div></div></div><div id="S24" class="sec sec-last"><h3>Retrospective analysis of statin dosing</h3><p id="P28" class="p p-first">We further examined the impact of genotype and clinical covariates on statin dose, retrospectively in two clinical populations (n = 579). The first cohort contained 224 patients taking atorvastatin and 37 patients taking rosuvastatin in the context of routine clinical care at a large academic center in the U.S.; the second cohort contained 121 patients taking atorvastatin and 198 patients taking rosuvastatin treated in a lipid clinic at a large academic center in Canada. Thus, we were able to assess the potential clinical utility of our model in the context of both primary and specialty care. Population characteristics of each cohort are described in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T4/" target="true" class="fig-table-link table figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a>.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T4"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T4/" target="table" rid-ob="ob-T4" rid-figpopup="T4" class="table img_link icnblk_img figpopup"><img alt="Table 4" title="Table 4" class="small-thumb" src="./PMC3922121_files/saved_resource(3)" src-large="/pmc/articles/PMC3922121/table/T4/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T4/" target="table" rid-figpopup="T4" rid-ob="ob-T4">Table 4</a></div><!--caption a4--><div><span>Population characteristics of retrospective atorvastatin and rosuvastatin dosing cohort</span></div></div></div><p id="P29">For these clinical practice-based cohorts, the relationship between genotype, age, and most recent statin dose has been summarized in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F3/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3</span></a>. We observed that patients taking 5 mg rosuvastatin were older than those taking 10 mg and 40 mg (p &lt; 0.05). The average ages are 64 years (S.D. 13.7) for the group taking 5 mg daily vs 55 (13.3) and 54 (14.4) for groups taking 10 mg and 40 mg, respectively. The transporter genotypes associated with statin concentration were not differently distributed among statin dose, implying that physicians may not yet have dosed each respective patient to their optimal serum statin level. Utilizing the genotypes and ages of these subjects to determine the dose recommended by our model indicates that only those patients at the highest doses exceeded the recommended dose (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T5/" target="true" class="fig-table-link table figpopup" rid-figpopup="T5" rid-ob="ob-T5" co-legend-rid=""><span>Table 5</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><img src="./PMC3922121_files/nihms-518688-f0003.gif" class="small-thumb" alt="Figure 3" title="Figure 3" src-large="/pmc/articles/PMC3922121/bin/nihms-518688-f0003.jpg"></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a4--><div><span>Distribution of transporter genotypes and age among atorvastatin (A) doses of 10, 20, 40, or 80 mg daily and rosuvastatin (B) doses of 5, 10, 20, or 40 mg daily in retrospective analysis of statin-treated patients. Age is depicted on the left y-axis with</span> <strong>...</strong></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T5"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T5/" target="table" rid-ob="ob-T5" rid-figpopup="T5" class="table img_link icnblk_img figpopup"><img alt="Table 5" title="Table 5" class="small-thumb" src="./PMC3922121_files/saved_resource(4)" src-large="/pmc/articles/PMC3922121/table/T5/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/table/T5/" target="table" rid-figpopup="T5" rid-ob="ob-T5">Table 5</a></div><!--caption a4--><div><span>Accuracy of dose prediction in retrospective analysis of atorvastatin and rosuvastatin dosing</span></div></div></div><p id="P30" class="p p-last">Among 67 patients on high-dose rosuvastatin (40 mg) or atorvastatin (80 mg), nearly 50% exceeded the maximum dose recommended by our model, suggesting that many were at risk of developing intolerance. Of the 16 patients taking high-dose atorvastatin (80 mg) within our cohort derived from an EMR-linked biobank, 9 exceeded the maximum recommended dose, and only 7 of these patients were still on 80 mg atorvastatin one year later. Conversely, all (7 of 7) subjects predicted by our algorithm to tolerate 80 mg were still on high-dose atorvastatin one year later, however, this result was not statistically significant (p = 0.48, Fisher's exact test). Collectively, these observations suggest that clinicians may benefit from the use of this model, when weighing the risks and benefits of implementing a high dose prospectively.</p></div></div><div id="S25" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S25title">Discussion</h2><p id="P31" class="p p-first">This study investigated the relationship between common drug transporter polymorphisms and plasma concentrations of atorvastatin and rosuvastatin in a real world population. We found a marked, 45-fold interpatient variability in observed plasma level, especially at the higher doses. In our clinical situation, where statin dose has been titrated to effect, statin transporter polymorphisms are associated with a detectable change in statin level. Indeed, nearly 90% of the explainable variability in rosuvastatin concentration can be accounted for by two reduced function transporter polymorphisms, in the uptake transporter <em>SLCO1B1</em> and the efflux transporter <em>ABCG2</em>. In contrast, explainable variability in atorvastatin level is almost equally divided between two polymorphisms in <em>SLCO1B1</em>, and the activity of CYP3A as measured by 4β-hydroxycholesterol concentration. Taking our findings together, we propose a dosing algorithm for atorvastatin and rosuvastatin that, based on our data regarding the association between transporter genotype, age, and statin concentration, would minimize risk for high plasma statin exposure.</p><p id="P32">Indeed, genetic polymorphisms in transport proteins contribute to interindividual variation in exposure to a number of drugs, including the statins<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660440">15</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660418">17</a></sup>. The <em>SLCO1B1</em> gene encodes organic anion-transporting polypeptide 1B1 (OATP1B1; previously known as OATP-C or OATP2); in 2001, our group was the first to identify functionally relevant single nucleotide polymorphisms (SNPs) in this transporter<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660411">18</a></sup>. Healthy subjects harboring certain <em>SLCO1B1</em> SNPs had higher plasma concentrations of such statins as atorvastatin, rosuvastatin, simvastatin, pravastatin, and pitavastatin<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660435">19</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660400">22</a></sup>. Importantly, a genome-wide analysis revealed an association between susceptibility to biochemical myopathy on high-dose simvastatin and a common reduced-function variant in <em>SLCO1B1</em>, namely c.521T&gt;C (rs4149056)<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660398">4</a></sup>. <em>SLCO1B1</em> c.521T&gt;C has also been associated with reduced LDL-C lowering response to rosuvastatin therapy<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660408">23</a></sup>. The other <em>SLCO1B1</em> polymorphism genotyped, c.388A&gt;G (rs2306283), appears, in vitro, to have activity equivalent to the reference sequence<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660409">18</a></sup>, and has been shown in some, but not all, healthy volunteer studies to be associated with a trend towards lower plasma atorvastatin level<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660407">22</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660397">24</a></sup>. Interestingly, the SEARCH study showed a link between this SNP and reduced risk for simvastatin-associated myopathy<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660406">4</a></sup>. In our population, the <em>SLCO1B1</em> c.521T&gt;C variant was not in Hardy-Weinberg equilibrium; it is possible that individuals homozygous for this variant are less likely to tolerate and remain on statin therapy. The ABCB1 polymorphism c.3435 T&gt;C was also not in equilibrium in our population, however, the reason for this result is unclear.</p><p id="P33">Polymorphisms in the ATP-binding cassette (ABC) efflux transporter <em>ABCG2</em> have been associated with higher rosuvastatin concentration in healthy volunteers<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660439">25</a></sup> and recently, with improved lipid lowering response in Korean subjects<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660412">26</a></sup> and Caucasians<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660401">23</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660430">27</a></sup>. The effect of reduced activity <em>ABCG2</em> polymorphism on rosuvastatin concentration suggests increased statin exposure is the mechanism resulting in the augmented lipid lowering response observed by other studies.</p><p id="P34">It is important to note that this study was conducted in a predominantly Caucasian population, and that caution may be warranted in extrapolating these results to other ethnicities. In particular, ethnicity-dependent differences have been observed in studies comparing statin pharmacokinetics in healthy volunteers of Asian and Caucasian ethnicity <sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660403">24</a></sup>. Moreover, in Asian countries such as Japan, the maximum approved dose of rosuvastatin is 20 mg/day compared with 40 mg/day in North American and European countries. Since the increase in rosuvastatin exposure is not strictly related to environment <sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660436">24</a></sup>, physicians in North America and Europe treating patients of Asian descent should be particularly aware that the maximum recommended dose of 40 mg/day may not be appropriate.</p><p id="P35">It has long been recognized that there is significant interindividual variation in CYP3A activity; however, the genetic basis for this variability has remained elusive. 4β-hydroxycholesterol is produced by CYP3A enzymes from cholesterol, and has been proposed to be a marker of CYP3A activity in vivo<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660420">28</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660414">29</a></sup>. In our population, low 4β-hydroxycholesterol level was associated with higher atorvastatin but not rosuvastatin concentration. Rosuvastatin concentration was also not associated with CYP2C9 *2 and CYP2C9 *3 genotypes, consistent with previous studies which have indicated that rosuvastatin is predominantly eliminated unchanged<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660438">30</a></sup>. Previous reports have associated reduced CYP3A function with higher creatine kinase levels in patients taking atorvastatin, suggesting these individuals are prone to more severe myopathy<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660425">31</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660410">32</a></sup>. Numerous drug interaction studies have described increased risk of adverse events resulting from the concomitant use of CYP3A inhibitors and statins metabolized by CYP3A, particularly atorvastatin and simvastatin. The US Food and Drug Administration (US FDA) recommendations advocate for a reduced dose of these statins if moderate CYP3A inhibitors are prescribed, and for some potent CYP3A inhibitors, contraindicate their use entirely<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660441">33</a></sup>.</p><p id="P36">Finally, our study identified age as a significant factor in predicting the concentrations of atorvastatin and rosuvastatin in patients. Age has been recognized as a clinical risk factor for statin-induced muscle toxicity<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660424">5</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R34" rid="R34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660429">34</a></sup>. In early pharmacokinetic studies, age was associated with increased exposure to atorvastatin<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R35" rid="R35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660423">35</a></sup>, but not rosuvastatin<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R36" rid="R36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660443">36</a></sup>. Rosuvastatin clearance, however, is partially mediated by tubular secretion in the kidney, thus the reduced renal function associated with advanced age may account for this effect<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660442">30</a></sup>. Older patients are also more likely to take more medications, though the number of co-medications was not a significant predictor of atorvastatin or rosuvastatin concentrations in our population.</p><p id="P37">Lathosterol is a late intermediate in cholesterol synthesis that can be used to measure the efficacy of statin-mediated HMG-CoA reductase inhibition<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R37" rid="R37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660405">37</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R38" rid="R38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660399">38</a></sup>. In our population, plasma concentrations of atorvastatin and rosuvastatin did not correlate with lathosterol levels. This suggests statin concentration in the liver, not the plasma, is the most important factor in determining the inhibition of HMG-CoA reductase. Ezetimibe is a cholesterol absorption inhibitor that has been previously associated with lathosterol level<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R39" rid="R39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660413">39</a></sup>; here we observed that lathosterol level is increased in patients taking ezetimibe even when they are concurrently taking statins, which limit lathosterol synthesis by inhibiting HMG-CoA reductase.</p><p id="P38">Our analysis of statin dosing patterns indicates <em>SLCO1B1</em> and <em>ABCG2</em> variant carriers were distributed throughout the dosing groups (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/figure/F3/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3</span></a>), indicating physicians did not adjust dose based on the altered pharmacokinetics profile caused by these variants. This suggests that, based on clinical presentation alone, it is not possible for clinicians to detect those that are driven by pharmacokinetics-related mechanisms linked to polymorphisms in <em>SLCO1B1</em> and <em>ABCG2</em>, and thus preventable by lowering the dose.</p><p id="P39">At the highest available dose, nearly 50% of patients taking atorvastatin or rosuvastatin exceeded the maximum genotype-based dose recommended by our algorithm. At lower doses, no patient in our cohort exceeded the maximum dose recommended by our algorithm, though it is important to note that rare individuals, not represented in our cohort, may in fact exceed their recommended dose even at lower doses. Taken together, genetic testing may be most useful when a patient is starting the highest dose of atorvastatin or rosuvastatin, bearing in mind that <em>SLCO1B1</em> c.521 T&gt;C variant carriers in particular are more likely to require higher doses as a result of reduced hepatic uptake.</p><p id="P40" class="p p-last">Here we present the range of atorvastatin and rosuvastatin concentrations in a patient population, providing a framework by which to assess normal variability in statin concentration, and identify the relationship between statin exposure and common statin transporter polymorphisms. In the clinical review of rosuvastatin originally submitted to the US FDA, all patients with serious adverse events for whom drug levels were available (n = 6) had high rosuvastatin concentrations (&gt; 50 ng/mL; <a href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_Crestor_Medr_P4.pdf" ref="reftype=extlink&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_Crestor_Medr_P4.pdf</a>). The FDA recently updated advice on statin risk to include memory loss and diabetes (<a href="http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm" ref="reftype=extlink&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm</a>), indicating that we do not yet fully understand the consequences of statin exposure systemically. While several groups have called for transporter genetics-guided statin dosing<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660431">4</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660404">8</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660427">26</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660444">27</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#R40" rid="R40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_354660445">40</a></sup> to our knowledge, this study is the first to propose guidelines based on interindividual differences in statin concentration. These guidelines provide a maximum starting dose in order to reduce the risk for high plasma statin concentration. Controlled, randomized trials are required to determine whether statin myopathy is reduced if statins are prescribed using this approach. In summary, this initial report of prospectively assessed plasma statin level and transporter genotypes in a patient care setting creates a framework for individualized statin selection and dosing.</p></div><div id="SM" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="SMtitle">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>1</h4><div class="sup-box half_rhythm" id="d36e860"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/bin/NIHMS518688-supplement-1.pdf">Click here to view.</a><sup>(83K, pdf)</sup></div></div><div class="sec suppmat" id="SD2"><h4>2</h4><div class="sup-box half_rhythm" id="d36e864"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/bin/NIHMS518688-supplement-2.docx">Click here to view.</a><sup>(16K, docx)</sup></div></div></div><div id="S26" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S26title">Acknowledgments</h2><div class="sec"><p id="__p1">The authors wish to thank Brooke Kennedy and Julie Lorenzin for help with blood sampling, and Cameron Ross, Adam McIntyre, and Matthew Ban for technical assistance.</p><p id="__p2"><strong>Funding Sources:</strong> This work was supported by grants from the Canadian Institutes of Health Research (MOP-89753), the Drug Safety and Effectiveness Network (DESN-PREVENT) and Wolfe Medical Research Chair in Pharmacogenomics to Richard Kim, and Academic Medical Organization of Southwestern Ontario Alternate Funding Plan Innovation Fund to Richard Kim, George Dresser and Kathryn Myers. BioVU is supported by the National Institutes of Health (UL1RR024975). Marianne DeGorter is the recipient of a Vanier Canada Graduate Scholarship from the Canadian Institutes of Health Research.</p></div></div><div id="__fn-groupid1056115" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-21"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-22">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__fn-groupid1056115title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN1"></p><p id="P41" class="p p-first-last"><strong>Conflict of Interest Disclosures:</strong> Dr Robert Hegele serves on the advisory board and speaker's bureau of Abbott, Aegerion, Amgen, AstraZeneca, Merck, Pfizer, Roche, Sunovion, and Valeant. The other authors declare no conflict of interest.</p><p></p><p class="fn sec" id="FN2"></p><p id="P42" class="p p-first-last"><strong>Publisher's Disclaimer: </strong>This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</p><p></p></div></div><div id="__ref-listid1005937" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-23"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-24">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid1005937title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al.  2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. <span><span class="ref-journal">Can J Cardiol. </span>2009;<span class="ref-vol">25</span>:567–579.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782500/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19812802" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: Impact of the 2001 national cholesterol education program guidelines. <span><span class="ref-journal">Ann Pharmacother. </span>2008;<span class="ref-vol">42</span>:1208–1215.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18648016" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">US Department of Health and Human Services  <span><span class="ref-journal">Health, United States, 2010, with special feature on death and dying. </span>2011</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">359</span>:789–799.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18650507" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Joy TR, Hegele RA. Narrative review: Statin-related myopathy. <span><span class="ref-journal">Ann Intern Med. </span>2009;<span class="ref-vol">150</span>:858–868.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19528564" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. <span><span class="ref-journal">Am J Cardiol. </span>2006;<span class="ref-vol">97</span>:69C–76C.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16581332" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. <span><span class="ref-journal">Cardiovasc Drugs Ther. </span>2005;<span class="ref-vol">19</span>:403–414.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16453090" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Niemi M. Transporter pharmacogenetics and statin toxicity. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2010;<span class="ref-vol">87</span>:130–133.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19890253" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. <span><span class="ref-journal">Annu Rev Pharmacol Toxicol. </span>2012;<span class="ref-vol">52</span>:249–273.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21942630" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Ritchie MD, Denny JC, Crawford DC, Ramirez AH, Weiner JB, Pulley JM, et al.  Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">86</span>:560–572.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850440/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20362271" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, Kim RB. Disposition of atorvastatin, rosuvastatin, and simvastatin in Oatp1b2−/− mice and intraindividual variability in human subjects. <span><span class="ref-journal">J Clin Pharmacol. </span>2012;<span class="ref-vol">9</span>:986–95.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/22167570" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Honda A, Yamashita K, Hara T, Ikegami T, Miyazaki T, Shirai M, et al.  Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. <span><span class="ref-journal">J Lipid Res. </span>2009;<span class="ref-vol">50</span>:350–357.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18815436" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Honda A, Yamashita K, Miyazaki H, Shirai M, Ikegami T, Xu G, et al.  Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. <span><span class="ref-journal">J Lipid Res. </span>2008;<span class="ref-vol">49</span>:2063–2073.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18503032" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">R Development Core Team  . <span class="ref-journal">R: A language and environment for statistical computing.</span> R Foundation for Statistical Computing; Vienna, Austria: 2012.   <a href="http://www.r-project.org/" ref="reftype=extlink&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.R-project.org</a>.</span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al.  Membrane transporters in drug development. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2010;<span class="ref-vol">9</span>:215–236.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326076/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20190787" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Gradhand U, Kim RB. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). <span><span class="ref-journal">Drug Metab Rev. </span>2008;<span class="ref-vol">40</span>:317–354.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18464048" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. <span><span class="ref-journal">Pharmacogenomics. </span>2008;<span class="ref-vol">9</span>:597–624.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18466105" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. <span><span class="ref-journal">J Biol Chem. </span>2001;<span class="ref-vol">276</span>:35669–35675.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11477075" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2007;<span class="ref-vol">82</span>:726–733.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17473846" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2006;<span class="ref-vol">16</span>:873–879.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17108811" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, et al.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2007;<span class="ref-vol">17</span>:647–656.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063287/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17622941" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, et al.  Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2005;<span class="ref-vol">78</span>:342–350.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16198653" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: The justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER) trial. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2012;<span class="ref-vol">5</span>:257–264.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/22331829" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2005;<span class="ref-vol">78</span>:330–341.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16198652" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation">Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2009;<span class="ref-vol">86</span>:197–203.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19474787" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, et al.  ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2010;<span class="ref-vol">87</span>:558–562.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20130569" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, et al.  Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: The GEOSTAT-1 study. <span><span class="ref-journal">Circ Cardiovasc Genet. </span>2010;<span class="ref-vol">3</span>:276–285.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20207952" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al.  Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: Evidence for involvement of cytochrome P450 3A4. <span><span class="ref-journal">J Biol Chem. </span>2001;<span class="ref-vol">276</span>:38685–38689.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11514559" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Diczfalusy U, Nylen H, Elander P, Bertilsson L. 4beta-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2011;<span class="ref-vol">71</span>:183–189.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040538/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21219398" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="element-citation">Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. <span><span class="ref-journal">Clin Ther. </span>2003;<span class="ref-vol">25</span>:2553–2563.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14667956" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="element-citation">Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2005;<span class="ref-vol">15</span>:415–421.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15900215" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="element-citation">Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2005;<span class="ref-vol">4</span>:911–918.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16264434" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="element-citation">Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">365</span>:285–287.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/21675881" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="element-citation">Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. <span><span class="ref-journal">JAMA. </span>2003;<span class="ref-vol">289</span>:1681–1690.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12672737" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="element-citation">Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR. Effect of age and gender on pharmacokinetics of atorvastatin in humans. <span><span class="ref-journal">J Clin Pharmacol. </span>1996;<span class="ref-vol">36</span>:242–246.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8690818" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="element-citation">Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-Coa reductase inhibitor. <span><span class="ref-journal">J Clin Pharmacol. </span>2002;<span class="ref-vol">42</span>:1116–1121.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12362926" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="element-citation">Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. <span><span class="ref-journal">J Lipid Res. </span>1988;<span class="ref-vol">29</span>:1149–1155.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/3183524" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="element-citation">De Cuyper I, Wolthers BG, van Doormaal JJ, Wijnandts PN. Determination of changes in serum lathosterol during treatment with simvastatin to evaluate the role of lathosterol as a parameter for whole body cholesterol synthesis. <span><span class="ref-journal">Clin Chim Acta. </span>1993;<span class="ref-vol">219</span>:123–130.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8306452" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="element-citation">Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al.  Inhibition of intestinal cholesterol absorption by ezetimibe in humans. <span><span class="ref-journal">Circulation. </span>2002;<span class="ref-vol">106</span>:1943–1948.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12370217" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="element-citation">Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al.  The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2012;<span class="ref-vol">92</span>:112–117.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384438/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/22617227" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3922121&amp;issue-id=233729&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#__abstractid1030492title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#S4title">Introduction</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#S5title">Methods</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#S17title">Results</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#S25title">Discussion</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#SMtitle">Supplementary Material</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#S26title">Acknowledgments</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#__fn-groupid1056115title">Footnotes</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#__ref-listid1005937title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/?report=reader"><img src="./PMC3922121_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/pdf/nihms-518688.pdf">PDF (1.0M)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" data-citationid="PMC3922121" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3922121%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3922121_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3922121%2F&amp;text=Clinical%20and%20Pharmacogenetic%20Predictors%20of%20Circulating%20Atorvastatin%20and%20Rosuvastatin%20Concentration%20in%20Routine%20Clinical%20Care" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3922121_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3922121%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3922121_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="23876492" data-aiid="3922121" data-aid="3922121" data-iid="233729" data-domainid="319" data-domain="nihpa" data-accid="PMC3922121" data-md5="747504ffb40788258ac2144df544b084"><img src="./PMC3922121_files/3631476" align="absmiddle" alt="Loading..."> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC3922121_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:27:07-04:00&amp;Host=ptpmc202">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC3922121_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC3922121_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC3922121_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=nihpa&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC3922121/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC3922121_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>